Hyposalivation in elderly patients

Journal of the Canadian Dental Association

Volumn 72, Issue 9, 2006, Pages 841-846

  Gupta, Anurag ^a   Epstein, Joel B ^a   Sroussi, Herve ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aging physiology; Salivary glands secretion; Xerostomia etiology; Xerostomia therapy

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC AGENT; RECOMBINANT INTERFERON; SALIVA SUBSTITUTE;

AGED; AGING; DENTAL CARIES; HUMAN; PHYSIOLOGY; REVIEW; SALIVARY GLAND; SECRETION; SJOEGREN SYNDROME; SKULL IRRADIATION; XEROSTOMIA;

AGED; AGING; CHOLINERGIC ANTAGONISTS; CRANIAL IRRADIATION; DENTAL CARIES; HUMANS; INTERFERON TYPE I, RECOMBINANT; MUSCARINIC AGONISTS; SALIVA, ARTIFICIAL; SALIVARY GLANDS; SJOGREN'S SYNDROME; XEROSTOMIA;

EID: 33750980677     PISSN: 14882159     EISSN: 14882159     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Baum BJ. Evaluation of stimulated parotid saliva flow rate in different age groups. J Dent Res 1981; 60(7):1292-6.
2. Heft MW, Baum BJ. Unstimulated and stimulated parotid salivary flow rate in individuals of different ages. J Dent Res 1984; 63(10):1182-5.
3. Aguirre A, Levine MJ, Cohen RE, Tabak LA. Immunochemical quantitation of alpha-amylase and secretory IgA in parotid saliva from people of various ages. Arch Oral Biol 1987; 32(4):297-301.
4. Percival RS, Challacombe SJ, Marsh PD. Flow rates of resting whole and stimulated parotid saliva in relation to age and gender. J Dent Res 1994; 73(8):1416-20.
5. Challacombe SJ, Percival RS, Marsh PD. Age related changes in immunoglobulin isotypes in whole and parotid saliva and serum in healthy individuals. Oral Microbiol Immunol 1995; 10(4):202-7.
6. Ship JA, Baum BJ. Is reduced salivary flow normal in old people? Lancet 1990(8729); 336:1507.
7. Wu AJ, Atkinson JC, Fox PC, Baum BJ, Ship JA. Cross-sectional and longitudinal analyses of stimulated parotid salivary constituents in healthy, different-aged subjects. J Gerontol 1993; 48(5):M219-24.
8. Ship JA, Nolan NE, Puckett SA. Longitudinal analysis of parotid and submandibular salivary flow rates in healthy, different-aged adults. J Gerontol A Biol Sci Med Sci 1995; 50(5):M285-9.
9. Ship JA, Pillemer SR, Baum BJ. Xerostomia in the geriatric patient. J Am Geriatr Soc 2002; 50(3):535-43.
10. Schein OD, Hochberg MC, Munoz B, Tielsch JM, Bandeen-Roche K, Provost T, and others. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med 1999; 159(12):1359-63.
11. Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. Curr Opin Rheumatol 2000; 12(5):391-398.
12. van der Reijden WA, Vissink A, Veerman EC, Amerongen AV. Treatment of oral dryness related complaints (xerostomia) in Sjogren's syndrome. Ann Rheum Dis 1999; 58(8):465-74.
13. Henson BS, Inglehart MR, Eisbruch A, Ship JA. Preserved salivary output and xerostomia-related quality of life in head and neck cancer patients receiving parotid-sparing radiotherapy. Oral Oncol 2001; 37(1):84-93.
14. Atkinson JC, Wu AJ. Salivary gland dysfunction: causes, symptoms, treatment. J Am Dent Assoc 1994; 125(4):409-16.
15. Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dent Assoc 1987; 115(4):581-4.
16. Navazesh M, Christensen C, Brightman V. Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res 1992; 71(7):1363-69.
17. Tapper-Jones L, Aldred M, Walker DM. Prevalence and intraoral distribution of Candida albicans in Sjogren's syndrome. J Clin Pathol 1980; 33(3):282-7.
18. Lundstrom IM, Lindstrom FD. Subjective and clinical oral symptoms in patients with primary Sjogren's syndrome. Clin Exp Rheumatol 1995; 13(6):725-31.
19. Rhodus NL, Bloomquist C, Liljemark W, Bereuter J. Prevalence, density, and manifestations of oral Candida albicans in patients with Sjogren's syndrome. J Otolaryngol 1997; 26(5):300-5.
20. Soto-Rojas AE, Villa AR, Sifuentes-Osornio J, Alarcon-Segovia D, Kraus A. Oral candidiasis and Sjogren's syndrome. J Rheumatol 1998; 25(5):911-5.
21. Scully C, Felix DH. Oral medicine - update for the dental practitioner: dry mouth and disorders of salivation. Br Dent J 2005; 199(7):423-7.
22. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res 1987; 66(Spec No):648-53.
23. Greenspan D. Xerostomia: diagnosis and management. Oncology 1996; 10(3 Suppl):7-11.
24. Dry mouth. National Institutes of Health and National Institute of Dental and Craniofacial Research. Bethesda, MD: 1999. Available from URL: http://www.nidcr.nih.gov/HealthInformation/DiseasesAndConditions/ DryMouthXerostomia/DryMouth.htm (accessed September 2006).
25. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth - 2nd edition. Gerodontology 1997; 14(1):33-47.
26. Chrischilles EA, Foley DJ, Wallace RB, Lemke Jh, Semla TP, Hanlon JT, and others. Use of medications by persons 65 and over: data from the established populations for epidemiologic studies of the elderly. J Gerontol 1992; 47(5):M137-44.
27. Narhi TO. Prevalence of subjective feelings of dry mouth in the elderly. J Dent Res 1994; 73(1):20-5.
28. Harrison T, Bigler L, Tucci M, Pratt L, Malamud F, Thigpen JT, and others. Salivary slgA concentrations and stimulated whole saliva flow rates among women undergoing chemotherapy for breast cancer: an exploratory study. Spec Care Dentist 1998; 18(3): 109-12.
29. Meurman JH, Laine P, Keinanen S, Pyrhonen S, Teerenhovi L, Lindqvist C. A longitudinal follow-up of salivary secretions in bone marrow transplant patients. Oral Surg Oral Med Oral Path Oral Radiol Endo 1997; 83(4):447-52.
30. Allweiss P, Braunstein GD, Karz A, Waxman A. Sialadenitis following 1-131 therapy for thyroid carcinoma: concise communication. J Nucl Med 1984; 25(7):755-8.
31. Hunter KD, Wilson WS. The effects of antidepressant drugs on salivary flow and content of sodium and potassium ions in human parotid saliva. Arch Oral Biol 1995; 40(11):983-9.
32. Trindade E, Menon D, Topfer LA, Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998; 159(10):1245-52.
33. Scully C, Epstein JB. Oral health care for the cancer patient. Eur J Cancer B Oral Oncol 1996; 32B(5):281-92.
34. Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, and others. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17(10):3333-55.
35. Ship JA, Eisbruch A, D'Hondt E, Jones RE. Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: one-year results. J Dent Res 1997; 76(3):807-13.
36. Eisbruch A, Ten Haken RK, Kim HM, Marsh LH, Ship JA. Dose, volume, and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer. Int J Radiat Oncol Biol Phys 1999; 45(3):577-87.
37. Chambers MS, Garden AS, Kies MS, Martin JW. Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management. Head Neck 2004; 26:9(796-807).
38. Sreebny LM, Yu A. Green A, Valdini A. Xerostomia in diabetes mellitus. Diabetes Care 1992; 15(7):900-4.
39. Epstein JB, van der Meij EH, Lunn R, Stevenson-Moore P. Effects of compliance with fluoride gel application on caries and caries risk in patients after radiation therapy for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 82(3):268-75.
40. Joyston-Bechal S, Hayes K, Davenport ES, Hardie JM. Caries incidence, mutans streptococci and lactobacilli in irradiated patients during a 12-month preventive programme using chlorhexidine and fluoride. Caries Res 1992; 26(5):384-90.
41. Burt BA. The use of sorbitol- and xylitol-sweetened chewing gum in caries control. J Am Dent Assoc 2006; 137(2):190-6.
42. Gorsky M, Epstein JB, Parry J, Epstein MS, Le ND, Silverman S Jr. The efficacy of pilocarpine and bethanechol upon saliva production in cancer patients with hyposalivation following radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97(2):190-5.
43. Fox PC, van der Ven PF, Baum BJ, Mandel ID. Pilocarpine for the treatment of xerostomia associated with salivary gland dysfunction. Oral Surg Oral Med Oral Pathol 1986; 61(3):243-8.
44. Fox PC, Atkinson JC, Macynski AA, Wolff A, Kung DS, Valdez IH, and others. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia). Arch Intern Med 1991; 151(6):1149-52.
45. Kao HJ, Lin HR, Lo YL, Yu SP. Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. J Pharm Pharmacol 2006; 58(2):179-86.
46. Epstein JB, Decoteau WE, Wilkinson A. Effect of Sialor in treatment of xerostomia in Sjogren's syndrome. Oral Surg Oral Med Oral Pathol 1983; 56(5):495-9.
47. Epstein JB, Schubert MM. Synergistic effect of sialagogues in management of xerostomia after radiation therapy. Oral Surg Oral Med Oral Pathol 1987; 64(2):179-82.
48. Cummins MJ, Papas A, Kammer GM, Fox PC. Treatment of primary Sjogren's syndrome with low-dose human interferon alfa administered by the oromucosal route: combined phase III results. Arthritis Rheum 2003; 49(4):585-93.
49. Khurshudian AV. A pilot study to test the efficacy of oral administration of interferon-alpha lozenges to patients with Sjogren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95(1):38-44.
50. Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjogren's syndrome. J Interferon Cytokine Res 1998; 18(4):255-62.
51. Bartels CL. Xerostomia information for dentists. Newport Beach, CA: Oral Cancer Foundation. Available from URL: www.oralcancerfoundation.org/dental/ xerostomia.htm (accessed September 2006).
52. Epstein JB, Stevenson-Moore P. A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction. Spec Care Dentist 1992; 12(1):21-3.